These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 32273277)
1. A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models. Zheng L; Ren L; Kouhi A; Khawli LA; Hu P; Kaslow HR; Epstein AL Clin Cancer Res; 2020 Jul; 26(14):3694-3706. PubMed ID: 32273277 [TBL] [Abstract][Full Text] [Related]
2. Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms. Wu S; Luo Q; Li F; Zhang S; Zhang C; Liu J; Shao B; Hong Y; Tan T; Dong X; Chen B Br J Haematol; 2024 Oct; 205(4):1361-1373. PubMed ID: 38960449 [TBL] [Abstract][Full Text] [Related]
3. TREM1/Dap12-based CAR-T cells show potent antitumor activity. Chen B; Zhou M; Zhang H; Wang C; Hu X; Wang B; Wang E Immunotherapy; 2019 Aug; 11(12):1043-1055. PubMed ID: 31268375 [No Abstract] [Full Text] [Related]
4. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. Zheng L; Hu P; Wolfe B; Gonsalves C; Ren L; Khawli LA; Kaslow HR; Epstein AL Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261129 [TBL] [Abstract][Full Text] [Related]
5. Fully human antibody V Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386 [TBL] [Abstract][Full Text] [Related]
6. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication. Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627 [TBL] [Abstract][Full Text] [Related]
7. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927 [TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells. Qin H; Edwards JP; Zaritskaya L; Gupta A; Mu CJ; Fry TJ; Hilbert DM; LaFleur DW Mol Ther; 2019 Jul; 27(7):1262-1274. PubMed ID: 31043341 [TBL] [Abstract][Full Text] [Related]
9. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer. Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M Immunology; 2024 Jul; 172(3):362-374. PubMed ID: 38469682 [TBL] [Abstract][Full Text] [Related]
10. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239 [TBL] [Abstract][Full Text] [Related]
13. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A Front Immunol; 2021; 12():665970. PubMed ID: 34475869 [TBL] [Abstract][Full Text] [Related]
14. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440 [TBL] [Abstract][Full Text] [Related]
15. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Sommermeyer D; Hill T; Shamah SM; Salter AI; Chen Y; Mohler KM; Riddell SR Leukemia; 2017 Oct; 31(10):2191-2199. PubMed ID: 28202953 [TBL] [Abstract][Full Text] [Related]
16. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647 [TBL] [Abstract][Full Text] [Related]
17. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Wang E; Wang LC; Tsai CY; Bhoj V; Gershenson Z; Moon E; Newick K; Sun J; Lo A; Baradet T; Feldman MD; Barrett D; Puré E; Albelda S; Milone MC Cancer Immunol Res; 2015 Jul; 3(7):815-26. PubMed ID: 25941351 [TBL] [Abstract][Full Text] [Related]
18. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell. Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736 [TBL] [Abstract][Full Text] [Related]
19. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099 [TBL] [Abstract][Full Text] [Related]
20. Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice. Chen R; Wang M; Liu Q; Wu J; Huang W; Li X; Du B; Xu Q; Duan J; Jiao S; Lee HS; Jung NC; Lee JH; Wang Y; Wang Y Cancer Lett; 2020 Jan; 469():162-172. PubMed ID: 31634527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]